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Abstract
Background: Airway smooth muscle (ASM) contraction underlies acute bronchospasm in asthma. ASM
cells can switch between a synthetic-proliferative phenotype and a contractile phenotype. While the
effects of extracellular matrix (ECM) components on modulation of ASM cells to a synthetic phenotype
have been reported, the role of ECM components on maturation of ASM cells to a contractile phenotype
in adult lung is unclear. As both changes in ECM components and accumulation of contractile ASM are
features of airway wall remodelling in asthma, we examined the role of the ECM protein, laminin, in the
maturation of contractile phenotype in human ASM cells.
Methods: Human ASM cells were made senescence-resistant by stable expression of human telomerase
reverse transcriptase. Maturation to a contractile phenotype was induced by 7-day serum deprivation, as
assessed by immunoblotting for desmin and calponin. The role of laminin on ASM maturation was
investigated by comparing the effects of exogenous laminin coated on culture plates, and of soluble laminin
peptide competitors. Endogenous expression of laminin chains during ASM maturation was also measured.
Results:  Myocyte binding to endogenously expressed laminin was required for ASM phenotype
maturation, as laminin competing peptides (YIGSR or GRGDSP) significantly reduced desmin and calponin
protein accumulation that otherwise occurs with prolonged serum deprivation. Coating of plastic cell
culture dishes with different purified laminin preparations was not sufficient to further promote
accumulation of desmin or calponin during 7-day serum deprivation. Expression of α2, β1 and γ1 laminin
chains by ASM cells was specifically up-regulated during myocyte maturation, suggesting a key role for
laminin-2 in the development of the contractile phenotype.
Conclusion:  While earlier reports suggest exogenously applied laminin slows the spontaneous
modulation of ASM to a synthetic phenotype, we show for the first time that endogenously expressed
laminin is required for ASM maturation to the contractile phenotype. As endogenously expressed laminin
chains α2, β1 and γ1 are uniquely increased during myocyte maturation, these laminin chains may be key
in this process. Thus, human ASM maturation appears to involve regulated endogenous expression of a
select set of laminin chains that are essential for accumulation of contractile phenotype myocytes.
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Background
Remodelling of the airway wall is a feature of chronic
asthma and is characterized by a number of structural
changes including, but not limited to, increased mass of
contractile airway smooth muscle (ASM) [1], and fibrosis
resulting from the accumulation of extracellular matrix
proteins (ECM) [2,3]. ASM is a key determinant of airway
hyperresponsiveness and remodelling in asthma. Airway
myocytes are thought to have capacity to contribute to
remodelling due to their ability for graded, and reversible
phenotype switching, which confers broad functional
capacity [4,5]. At one extreme airway myocytes exist in an
immature phenotype that is characterised by a high ten-
dency for proliferation, expression and secretion of ECM
proteins, and synthesis of inflammatory mediators in
response to a number of environmental cues [4-7]. In con-
trast, myocytes of a mature phenotype serve a primarily
contractile function and are marked by a unique reper-
toire of cytoskeletal and contractile apparatus proteins;
including smooth muscle myosin heavy chain, SM22,
desmin and calponin [5,7-9]. Notably, however, there is
evidence that contractile smooth muscle cells are capable
of expressing ECM components such as glycosaminogly-
cans [10] and collagen [11], suggesting that ASM cells
exist in a functional phenotype that is intermediate to the
fully synthetic and contractile state.
Laminins are cross-shaped heterotrimeric glycoproteins of
the ECM that contain one copy each of an α-, β- and γ-
chain [12,13]. The expression of laminin is tissue depend-
ent and varies at different times during development [14].
In the lung, the most significant changes in the expression
pattern of laminin occurs between the pseudoglandular
and canalicular stage, during which differentiation of
ASM cells is initiated and the structural ordering of the air-
way wall is established [15].
Using antibodies that block laminin polymerisation or
receptor binding to laminin, Schuger and colleagues
[16,17] showed that lung mesenchymal cell spreading on
laminin-containing ECM is required for differentiation of
embryonic lung mesenchymal cells into ASM cells. More-
over, similar studies with embryonic mouse organotypic
and whole lung cultures reveal laminin is an essential
basement membrane component necessary for both pul-
monary branching morphogenesis, and for the circumfer-
ential alignment of ASM cells around the airway epithelia.
Laminin required for ASM differentiation and structural
organization of the airway is synthesized, in part, by the
developing myocytes themselves, as suppression of α1
laminin chain secretion using brefeldin A prevents myo-
cyte accumulation in the vicinity of developing epithelia
[18]. Notably, the airways of asthmatics show greater
immunoreactivity for the α2 and β2 laminin chains com-
pared with the airway wall of healthy controls [19]. Also,
cultured human ASM cells obtained from asthmatic
patients exhibit an altered expression profile of ECM pro-
teins that includes increased collagen type I and decreased
laminin  α1 chain [20]. Furthermore, cultured human
ASM cells stimulated with asthmatic serum produce
increased amounts of the γ1 chain of laminin [21]. Collec-
tively, these observations suggest that changes in the
endogenous expression of laminin by ASM cells may
occur in asthma, and this could be an essential determi-
nant of myocyte phenotype and function during disease
pathogenesis.
Hirst and colleagues [22] showed that primary cultured
human ASM cells grown on a laminin matrix proliferated
much more slowly, were less responsive to mitogens, and
expressed greater abundance of contractile proteins com-
pared with cells grown on a plastic or collagen type I
matrix. This suggests that exogenous laminin prevents the
spontaneous modulation of contractile ASM cells to a syn-
thetic/proliferative phenotype in cell culture. Given the
emerging evidence for ASM phenotype plasticity and its
potential association with pathogenesis of features of
asthma such as the accumulation of contractile ASM mass
and fibrosis of the airway wall, in the current study we
investigated whether laminin was required for the matu-
ration of ASM cells to a contractile phenotype in culture.
For our studies we used prolonged serum deprivation to
induce contractile phenotype maturation in human ASM
as we have previously described [9,23-25]. Based on
expression of desmin and calponin, which are well char-
acterised protein markers for the mature/contractile phe-
notype [8,26-29], we tested the requirement of
endogenously expressed laminin for contractile myocyte
maturation. By elucidating the cellular and molecular
mechanisms that regulate airway myocyte differentiation
and phenotype modulation we hope to better understand
the role of laminin in the contribution of ASM cells to the
pathogenesis of asthma.
Methods
Immortalized human airway smooth muscle cell culture
For all studies at least four senescence-resistant human
airway smooth muscle (HASM) cell lines were prepared
using MMLV retroviral vectors to facilitate stable integra-
tion of the human telomerase reverse transcriptase gene
(hTERT) as we have previously described [25]. The pri-
mary cultured HASM cells used to generate each cell line
were prepared as we have previously described from mac-
roscopically healthy segments of 2nd-to-4th generation
main bronchus obtained after lung resection surgery from
patients with a diagnosis of adenocarcinoma [30,31]. All
procedures were approved by the Human Research Ethics
Board (University of Manitoba). hTERT-expressing HASM
cells retain the ability to express markers of the contractile
phenotype including smooth muscle myosin heavy chain,Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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calponin, sm-α-actin, and desmin to passage 10 and
higher [25]. For all experiments, passages 16–22 cultures
were used. To induce 'contractile/mature' phenotype
expression in subpopulations of hTERT-HASM, confluent
cultures were maintained in Dulbecco's Modified Eagle's
Medium (DMEM) supplemented with ITS (insulin 5 μg/
ml; transferrin 5 μg/ml, selenium 5 ng/ml) for up to 7
days as we have described [9].
Experimental system
Human ASM cells were seeded onto 100 mm dishes and
left to grow to monolayer confluence in DMEM contain-
ing 10% v/v foetal bovine serum (FBS). The cells were
then trypsinised and replated onto 6-well plastic, or lam-
inin-coated culture dishes at a seeding density of 1 × 105
cells per well in DMEM containing 0.5% v/v FBS (prelim-
inary experiments confirmed that this seeding density was
sufficient to retain confluency in re-seeded cultures).
Before subsequent treatments, re-plated cultures were
incubated at 37°C for ~16 hrs, to ensure full cell adher-
ence and spreading [22,32] independent of any influences
on ASM proliferation induced by the ECM (as measured
from cell counts using the haemocytometer). To induce a
contractile phenotype, cells were then serum deprived for
up to 7 days in DMEM/ITS, a duration previously shown
by our laboratory to be sufficient to induce myocyte mat-
uration and increased expression of the smooth muscle
contractile apparatus protein; calponin, and the interme-
diate filament protein, desmin [9,33,34]. Serum-free
media was replaced with fresh DMEM/ITS every second
day.
To examine the role of laminin in the maturation of
HASM cells, laminin-competing peptides (1 μM) were
added at the time of serum deprivation and re-added
every second day when fresh serum-free media was
replaced. The YIGSR pentapeptide corresponds to the
929–933 sequence of the β chain of laminin [35] and is
found to compete with laminin for binding to the laminin
receptor. The YIGSR peptide (Sigma, Saint Louis, MO)
was reconstituted in distilled water to a stock concentra-
tion of 10 mM and then diluted to 1 μM final concentra-
tion in serum-free DMEM for use in experiments. The
GRGDSP peptide is derived from the amino acid sequence
of the α chain of laminin. The RGD amino acid sequence
is also found within fibronectin, where it was originally
identified as the sequence motif that mediates cell attach-
ment [36]. The GRGDSP and GRADSP peptides (Calbio-
chem, La Jolla, CA) were reconstituted in 5% acetic acid to
a stock concentration of 10 mM and then for use in exper-
iments was diluted in serum-free DMEM to 1 μM final
concentration as per previous reports [37]. In pilot exper-
iments (not shown), we determined that the highest con-
centration of vehicle acetic acid (0.0005%) was well
below the threshold concentration for influencing HASM
cell proliferation, desmin or calponin protein accumula-
tion.
Laminin coating of culture plates
To examine the effect of exogenous laminin, plastic cell
culture plates were coated with various forms of laminin
according to previously described methods [22]. For coat-
ing experiments, all laminin preparations were reconsti-
tuted in sterile PBS and then diluted to 10 μg/ml in PBS.
Briefly, each laminin preparation was adsorbed to 6-well
plates for 6 hrs at room temperature. Non-specific binding
sites were blocked for 30 minutes with PBS containing
0.1% w/v BSA, at room temperature. Prior to seeding of
cells onto the laminin-coated plates, the plates were
washed with DMEM. The laminin preparations used
included laminin prepared from Engelbreth-Holm-
Swarm (EHS) murine sarcoma (Sigma, St. Louis, MO)
that predominately consists of the laminin trimer α1, β1
and  γ1. The degree of homology between full length
murine and human laminin is at least 78%, with laminin
receptor binding domains exhibiting 100% homology
[14,38]. Two laminin preparations from freshly frozen
human placenta tissue were also used (gift from Dr J.
Wilkins of the University of Manitoba, Canada). Placental
laminin was isolated by affinity purification with mono-
clonal 4E10 or 5H2 antibodies, which recognize laminin
β1 and α2 chains, respectively [39,40].
Measurement of ASM mature-marker proteins
For analysis of myocyte phenotype, protein lysates were
harvested 16 hrs after re-plating (basal/Day 0) and follow-
ing 7 days serum-deprivation (Day 7). Cells were washed
twice with ice-cold PBS and extracted with ice-cold lysis
buffer (100 mM NaCl; 10 mM Tris-HCl, pH 7.5; 2 mM
EDTA; 0.5% w/v deoxycholate; 1% v/v triton X-100; 1 mM
phenylmethylsulphonylfluoride; 10 mM MgCl2; 5 μg/ml
aprotinin; 100 μM sodium orthovanadate). The cells were
scraped, transferred to 1.5 ml plastic tubes, centrifuged
(760 × g, 5 min) and the supernatant stored at -20°C. Pro-
tein content in supernatant samples was determined using
the Bio-Rad protein assay (BioRad, Hercules, CA). The
samples (12–15 μg protein per lane) were separated elec-
trophoretically under reducing conditions on an 8% SDS-
polyacrylamide gel and proteins were transferred onto
nitrocellulose membranes for western blotting. Mem-
branes were blocked with 5% w/v skim milk in Tris Buff-
ered Saline (10 mM Tris HCl, pH8, 150 mM NaCl) and
0.1% v/v Tween-20, then incubated with primary anti-
bodies, diluted in 1% w/v skim milk, to desmin (1:500
dilution) or calponin (1:2,000 dilution). The membranes
were developed by subsequent incubation with secondary
horseradish-peroxidase-conjugated antibody, then visual-
ized with enhanced chemiluminescence reagents (Amer-
sham, Buckinghamshire, UK). Membranes were re-
probed with antibodies for β-actin to normalize for equalRespiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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loading of all samples. Scanning and quantification of the
relative protein abundance was performed using the
Epson Perfection 4180 Station and TotalLab TL100 soft-
ware (Nonlinear Dynamics, Durham, NC). Protein results
were expressed as fold increment over basal (Day 0) rela-
tive to β-actin.
Real-Time PCR
Total RNA was extracted from hTERT-HASM cells cultured
in 6-well plates using the Qiagen RNeasy Mini Kit (Qia-
gen, Mississauga, ON) according to the manufacturer's
protocol. Total RNA (2 μg) was reversed transcribed using
M-MLV reverse transcriptase (Promega, Madison, WI),
incubated for 2 h at 37°C followed by 5 min incubation
at 95°C, and diluted 1:10 with RNase-free water. The
cDNA sample was further processed by Real-Time PCR
using the primer pairs listed in Table 1. Cycle parameters
were: denaturation at 92°C for 45 s, annealing at 60°C for
45 s and extension at 72°C for 90 s for 40 cycles. Assays
were performed in duplicate in 20 μl reactions and the
cycle threshold (CT = amplification cycle number) values
for each reaction were determined using Roche Molecular
Biochemicals LightCyler 3 (version 3.5). Real-Time PCR
data was analysed using the comparative CT method as
previously described [41]. The amount of target gene nor-
malised to an endogenous reference (18s rRNA, desig-
nated as ΔCT) and relative to a calibrator (Day 0,
designated as ΔΔCT) is given by the equation 2-ΔΔCT.
Materials
All chemicals used were of analytical grade or higher. All
compounds [mouse anti-calponin antibody (clone hCP,
C2687), YIGSR, laminin-EHS] were purchased from
Sigma (St. Luois, MO) unless stated otherwise. GRGDSP
and GRADSP peptides were obtained from Calbiochem
(EMB Biosciences Inc. La Jolla, CA). Rabbit anti-desmin
antibody (H-76, sc14026) was purchased from Santa Cruz
Biotechnology Inc (Santa Cruz, CA). Antibodies to lam-
inin chains α2, β1, β2 and γ1 were a gift from Dr. Eva
Engvall (The Burnham Institute, La Jolla, CA, USA).
Statistical analysis
Data are expressed as mean and standard error of the
mean (SEM) of observations obtained from ASM cells cul-
tured from at least four different cell lines. All experiments
were carried out in duplicate. Data were expressed as fold
increment over basal (Day 0) relative to β-actin (protein)
or 18s rRNA (mRNA) and results were analysed using one-
way ANOVA, with repeated measures, followed by Bon-
ferroni's post hoc t test, where appropriate. A probability
value of P < 0.05 was considered significant.
Results
Effect of blocking laminin binding on HASM maturation
We first assessed phenotype maturation by measuring the
abundance of stringent contractile phenotype marker pro-
teins desmin and calponin [5,8]. Under basal conditions,
16 hrs after replating myocytes from confluent cultures in
DMEM containing 0.5% FBS, HASM cells expressed low
levels of desmin and calponin. However, following 7-days
in serum deficient conditions, both desmin and calponin
protein increased markedly, exhibiting a doubling in
abundance (P < 0.05, Figure 1). This expression pattern is
consistent with phenotype maturation of ASM cell myo-
cytes that we have described previously for both hTERT
immortalized cells and primary cultured airway smooth
muscle cells [5,8,25].
We first examined whether laminin was required for
HASM maturation. HASM cells were incubated with lam-
inin mimetic peptides (1 μM), YIGSR and GRGDSP, that
competitively inhibit binding of endogenously expressed
laminin. The peptides were added ~16 hrs after replating
myocytes from confluent cultures and at the same time
that 0.5% FBS-supplemented DMEM was replaced with
serum-deficient DMEM; thereafter peptides and culture
media was replaced every second day. The peptide YIGSR
is a selective inhibitor of laminin as it corresponds to a
unique amino acid sequence on the laminin β1 chain
[42]. YIGSR has previously been reported to promote cell
attachment and migration, and to block angiogenesis and
Table 1: List of primers for laminin chains used in Real-Time PCR
Gene product NCBI accession number Primer sequences
Laminin α1 chain NM005559 Forward 5'TGG GTG TGG GAT TTC TTA GC 3'
Reverse 5'CCT GAC CGT CTA CCC AGT GT 3'
Laminin α2 chain NM000426 Forward 5'GGC TTA TTC AGC TGG CAG AG 3'
Reverse 5'ATT CTC CCA GGG ACT TTG CT 3'
Laminin β1 chain NM002291 Forward 5'AAC GTG GTT GGA AGA ACC TG 3'
Reverse 5'ACA CTC CCT GGA AAC AGT GG 3'
Laminin β2 chain NM002292 Forward 5'CCT AGC CCT GTG AGC AAC TC 3'
Reverse 5'GTC TGT CAG GCT CAG GGT GT 3'
Laminin γ1 chain NM002293 Forward 5'AAT CCG TAT GGG ACC ATG AA 3'
Reverse 5'TCA CAC CTC TCA CAG CCT TG 3'
18s rRNA [41, 89] Forward 5'CGC CGC TAG AGG TGA AAT TC 3'
Reverse 5'TTG GCA AAT GCT TTC GCT C 3'Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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Effect of laminin-competing peptides (YIGSR, 1 μM and GRGDSP, 1 μM) on (A) desmin and (B) calponin protein abundance fol- lowing 7-day serum deprivation Figure 1
Effect of laminin-competing peptides (YIGSR, 1 μM and GRGDSP, 1 μM) on (A) desmin and (B) calponin protein abundance fol-
lowing 7-day serum deprivation. YIGSR = peptide derived from the amino acid sequence of the β1 chain of the major receptor 
binding site in laminin; GRGDSP = amino acid sequence within fibronectin and other extracellular proteins that mediates cell 
attachment; GRADSP = inactive peptide for GRGDSP. Grouped data represent results obtained from three different cultures. 
* P < 0.05, compared with Day 0; † P < 0.05 compared with Day 7 response in the absence of peptide.Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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tumour metastases [42]. The GRGDSP peptide is semi-
selective for blocking laminin binding, as it corresponds
to the amino acid sequence on the short arm of the α
chain of laminin, which has sequence homology with the
binding region of other ECM proteins such as fibronectin
[43]. Selective blockade of laminin binding with YIGSR (1
μM) abrogated the accumulation of desmin and calponin
protein abundance that occurred in untreated cultures
after 7 days serum deprivation (Figure 1). Similarly, incu-
bation of cultures with GRGDSP prevented the accumula-
tion of the contractile phenotype marker proteins desmin
and calponin (Figure 1). Conversely the negative control
peptide, GRADSP [36] had no effect on phenotype matu-
ration, as desmin and calponin protein accumulation fol-
lowing 7-day serum deprivation was similar to untreated
controls (Figure 1). Importantly, the inhibitory effect of
YIGSR and GRGDSP was not the result of peptide-induced
cell toxicity as trypan blue exclusion was not increased
compared to untreated cultures. Neither YIGSR nor
GRGDSP induced detectable cell detachment or cell
rounding, and had little effect on myocyte morphology, as
seen by phase contrast imaging (Figure 2). Moreover, cell
number was unchanged between all treatment groups
(untreated cells at Day 7 = 1.0 ± 0.1 × 105; treated cells:
YIGSR = 1.0 ± 0.3 × 105; GRDGSP = 1.0 ± 0.3 × 105;
GRADSP = 1.0 ± 0.2 × 105 cells per well). Collectively,
these experiments reveal endogenously expressed laminin
is required for phenotype maturation of HASM cultured
in serum-free conditions.
Effect of exogenous laminin on HASM maturation
As previous work [22] clearly demonstrates that coating of
cell culture plates with exogenous laminin inhibits mod-
ulation of HASM to a proliferative phenotype, we next
examined whether coating of culture dishes with laminin
was sufficient to promote phenotype maturation and
increase the accumulation of desmin and calponin that
occurs with prolonged culture in serum-free conditions.
HASM cells were thus re-plated from serum-fed confluent
cultures on dishes pre-coated with different laminin prep-
arations, including (1) laminin from EHS tumours that
contains laminin type 1 (laminin 111) isoform, (2) affin-
ity purified β1 chain-containing laminin from human pla-
centa that includes laminin-1 (laminin 111), 2 (laminin
211), 6 (laminin 311), 8 (laminin 411), 10 (laminin 511)
isoforms, and (3) affinity purified α2 chain-containing
laminin from human placenta that consists of laminin-2
(laminin 211) and 4 (laminin 221). Cells were main-
tained for 7 days in serum deficient media and the accu-
mulation of desmin and calponin was then measured by
immunoblotting. Coating culture dishes with exogenous
laminin had no effect on HASM cell maturation, as the
change in abundance of desmin and calponin was not dif-
ferent from that measured for control cultures in which
cells were plated directly onto uncoated plastic culture
dishes (Figure 3).
For our studies we used a coating concentration of lam-
inin that was based on pilot experiments in which we con-
structed a laminin-EHS concentration response curve
(0.01–10 μg/ml) that optimised HASM attachment and
adherence in DMEM/0.5% FBS culture media. The con-
centration that we used for our subsequent studies (10 μg/
ml) was comparable to that used previously by other
groups [22,44]. Notably, in our studies the cell density fol-
lowing 7-day serum deprivation was not different
between HASM cells seeded onto plastic or laminin
(untreated cells = 1.0 ± 0.1 × 105 cells compared with cells
seeded onto laminin-EHS = 1.0 ± 0.4 × 105 cells per well).
Furthermore, coating with the different laminin prepara-
tions that we employed appeared to be equally effective,
as for all preparation HASM cells became organized into a
web-like pattern that is characteristic of smooth muscle
grown onto laminin coated dishes [22,44] (Figure 4). Col-
lectively, our experiments demonstrate that exogenously
applied laminin is not sufficient to promote HASM matu-
ration that occurs during prolonged growth in serum-defi-
cient culture conditions.
Profile of endogenous laminin chains synthesized by HASM 
cells
As our studies with laminin-binding peptide inhibitors
(Figure 1) indicate endogenously expressed laminin is
required for HASM maturation to a contractile phenotype,
we next assessed the pattern of laminin chains that are
expressed during 7-days serum deprivation. Real-Time
PCR analysis of mRNA from myocytes under Day 0 basal
conditions (16 hrs after re-plating from confluent serum-
fed cultures) revealed that both α1 and α2 laminin chains
are expressed, with the latter being the more abundant
(Table 2). In addition, abundant levels of mRNA for β1,
β2 and γ1 laminin chains of approximately equal magni-
tude were expressed by HASM cells (Table 2). Interest-
ingly, following 7-days serum deprivation, the level of
expression of the α2, β1 and γ1 laminin chain mRNAs was
increased by 4-, 3- and 2-fold, respectively, compared to
basal levels at Day 0 prior to serum deprivation (Figure
5A). An increase in the abundance of mRNA for α2, β1
and γ1 laminin chains was observed by 3-days serum dep-
rivation (data not shown) but this was much less marked
than at day 7 when our studies were completed. In con-
trast, abundance of mRNA for α1, β2 laminin chains was
unchanged following serum deprivation (Figure 5A). We
also performed complementary immunoblotting analyses
to assess whether changes in mRNA were reflected in the
abundance of the protein encoded by individual laminin
chain transcripts. Indeed the trend for increased expres-
sion of both α2 and β1 laminin chains that we observed
at the mRNA level was mirrored at protein level where α2Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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abundance was doubled and β1 was increased 30% (P <
0.05, Figure 5B). Furthermore, protein for γ1 laminin
chain was also increased by 55% (P < 0.05).
Discussion
This study was completed to extend understanding of the
role of laminin in phenotype expression of human ASM
Phase contrast images of ASM cells in the presence and absence of laminin-competing peptides (YIGSR, GRGDSP, GRADSP, 1  μM) following 7-day serum deprivation Figure 2
Phase contrast images of ASM cells in the presence and absence of laminin-competing peptides (YIGSR, GRGDSP, GRADSP, 1 
μM) following 7-day serum deprivation. YIGSR = peptide derived from the amino acid sequence of the β1 chain of the major 
receptor binding site in laminin; GRGDSP = amino acid sequence within fibronectin and other extracellular proteins that medi-
ates cell attachment and also correspond to the α chain of laminin; GRADSP = inactive peptide for GRGDSP. Bar = 70 μm.Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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Western blot analysis showing the effect of various types of laminin (LN) on (A) desmin and (B) calponin protein abundance Figure 3
Western blot analysis showing the effect of various types of laminin (LN) on (A) desmin and (B) calponin protein abundance. 
HASM cells were seeded onto plastic or laminin (10 μg/ml)-coated dishes and then serum deprived for 7 days. EHS = laminin 
from Engelbreth-Holm-Swarm murine sarcoma; β1 = affinity purified β1 chain-laminin from human placenta that includes LN-1, 
2, 6, 8, 10; α2 = affinity purified α2 chain-containing laminin from human placenta that includes LN-2 and 4. Grouped data rep-
resent results obtained from at least four different cultures. *P < 0.05, compared with Day 0 on plastic.Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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cells from the adult lung. There is ample evidence that
laminin has both anti-proliferative effects and slows spon-
taneous phenotype modulation of airway, visceral and vas-
cular smooth muscle cells [22,45-47]. However, despite a
number of elegant studies investigating mesenchyme dif-
ferentiation in airways of embryonic mouse lung cultures
[18], the direct role of laminin in phenotype maturation of
differentiated airway myocytes from the mature lung has
not been dissected. Our current studies using soluble pep-
tide inhibitors of laminin binding sites demonstrate for
the first time that laminin chains endogenously expressed
by HASM cells are required for maturation to a contractile
Phase contrast images of ASM cells in the presence and absence of different coating of laminin isoforms following 7-day serum  deprivation Figure 4
Phase contrast images of ASM cells in the presence and absence of different coating of laminin isoforms following 7-day serum 
deprivation. EHS = laminin from Engelbreth-Holm-Swarm murine sarcoma; β1 = affinity purified β1 chain-containing laminin 
from human placenta that includes LN-1, 2, 6, 8, 10; α2 = affinity purified α2 chain-containing laminin from human placenta that 
includes LN-2 and 4. Bar = 70 μm.Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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phenotype. This is supported by our observations that
each of the laminin competing peptides used, YIGSR and
GRGDSP, completely inhibited accumulation of contrac-
tile phenotype protein markers (desmin and calponin), in
a well established serum-free cell culture system that pro-
motes myocyte maturation [9,23,25]. Furthermore, we
have characterized the profile of laminin chains expressed
by our human airway myocyte cultures, and documented
that expression of the constituents of laminin-2 (α2, β1,
and  γ1 chains) increases concomitantly with myocyte
maturation. In addition, we show that in contrast to the
potential for exogenous laminin coated onto culture
dishes to prevent phenotype modulation, it is not suffi-
cient to augment endogenous laminin-dependent matu-
ration of cultured HASM. Collectively, these findings
demonstrate an essential role for endogenous laminin in
determining phenotype expression of HASM cells from
the adult lung, and thus could represent a mechanism for
intrinsic regulation of the contribution of HASM to
changes in airway structure in health and disease.
Laminin is a trimer consisting of three polypeptide chains,
α, β and γ, which possess a number of potential binding
sites for receptors including the integrins [48-55] and
other non-integrin subtypes [56-58]. A number of studies
have used soluble peptides that compete with known
sequences for laminin receptors, and these have generated
considerable understanding of the role of laminins in cell
biology. For our studies we use two active peptides, YIGSR
and GRGDSP, and an inactive control, GRADSP to modu-
late myocyte interactions with the ECM. As in previous
studies using other cell systems, the peptide inhibitors for
laminin binding that we used were well suited for in vitro
investigation, and thus provided an important tool to
determine the role of endogenously expressed laminins in
HASM phenotype maturation. None of the peptides
induced cell death or detachment. Consistent with pub-
lished studies [32,36,59-61] our preliminary experiments
did reveal that both active peptides prevent adhesion of
newly plated cells; this observation was a key element for
our experimental design, in which we only added pep-
tides in serum free media after re-plated myocytes had
fully attached and spread in the presence of 0.5% FBS.
The YIGSR peptide corresponds to amino acids 929–933
of the β chain of laminin [35] and has been used in
numerous experimental conditions in vitro and  in vivo
[42,62-66]. For example, YIGSR inhibits tumor growth
and tumor cell deposition in the bone, liver, and kidney
in a mouse model of B-cell lymphoma [66]. Also, YIGSR
reduces the formation of lung colonies in mice injected
with melanoma cells and inhibits melanoma cell migra-
tion in vitro [42]. We used YIGSR as a laminin-specific
inhibitor due to its selectively for a unique sequence in the
laminin β1 chain. As laminin β1 chain is a component of
a number of laminin isoforms we cannot be entirely cer-
tain which isoforms were most affected in our study, how-
ever based on our expression studies that show evidence
for concomitant increase in laminin α2 chain with serum
deprivation, it appears that laminin-2 was likely a princi-
pal target.
The GRGDSP peptide mimics sequence present in the α
chain of laminin that shares homology with a number of
other ECM proteins, such as fibronectin [36,61]. Hayman
and colleagues [37] showed that the threshold concentra-
tion of GRGDSP that induces normal rat kidney cell
detachment from fibronectin and vitronectin occurs at
concentrations above 1 μM. Though, we used a concentra-
tion of 1 μM for all peptides in the current study, the
effects of GRGDSP, which were similar to that for YIGSR,
cannot be exclusively attributed to the inhibition of lam-
inin binding. Nonetheless, in light of the similarity of the
cell responses to YIGSR or GRGDSP in our studies, it is
likely that effects of the latter on laminin interactions is a
significant element of the responses measured.
Different splice variants of the each of the α, β and γ lam-
inin chains can combine to produce at least 15 functional
laminin isoforms. Using immunohistochemical
approaches, various laminin chains have been shown to
be expressed in the lung and specifically in the airway
around smooth muscle bundles [15,19,67-72]. However
no studies to date have conclusively shown the presence
of distinct staining for specific laminin isoforms due to
lack of available antibodies that detect the presence of
laminin trimers. We used three different laminin prepara-
tions to coat culture dishes and assess the capacity of exog-
enous laminin to promote phenotype maturation of
HASM. EHS laminin is widely used and consists primarily
of laminin-1 [12]. As a broader spectrum of laminin iso-
forms is expressed in the lungs we also used laminin affin-
ity purified from human placenta using β1 laminin chain-
Table 2: Absolute ΔCT values for laminin chain mRNA 
expression
Gene product Laminin chain mRNA (absolute ΔCT values)
Day 0 Day 7
Laminin α1 chain 22.2 ± 0.5 23.5 ± 0.9
Laminin α2 chain 10.8 ± 0.9 8.8 ± 0.4
Laminin β1 chain 9.0 ± 0.5 7.5 ± 0.7
Laminin β2 chain 9.3 ± 0.3 8.8 ± 0.9
Laminin γ1 chain 8.8 ± 0.4 7.9 ± 0.6
CT = threshold cycle/amplification cycle number. ΔCT = difference 
between CT value for laminin chain gene of interest versus matched 
18s rRNA CT value. The smaller the ΔCT value the greater the mRNA 
expression. These absolute ΔCT values were used to calculate fold 
differences in mRNA levels presented in Figure 5 using the 
comparative CT method.Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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(A) mRNA expression of laminin chains by HASM cells at Day 0 (open bars) and following 7-day serum deprivation (closed  bars) Figure 5
(A) mRNA expression of laminin chains by HASM cells at Day 0 (open bars) and following 7-day serum deprivation (closed 
bars). Grouped data represent results obtained from three different cultures carried out in duplicate. (B) Western blot analysis 
showing the protein abundance of laminin chains at Day 0 (open bars) and following 7-day serum deprivation (closed bars). † P 
< 0.05, compared with the respective laminin chain at Day 0.Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
Page 12 of 15
(page number not for citation purposes)
selective antibodies. Many of the known laminin isoforms
possess a β1 chain, including laminin-1, 2, 6, 8, and 10
[14,69,73]. Laminins-2 (α2 β1γ1), 4 (α2 β2γ1), 8 (α4
β1γ1) and 10 (α5 β1γ1) are expressed in human placenta
[39,74,75], thus there is considerable overlap with lam-
inins expressed in the lung. To assess the effects of a more
defined lung-relevant laminin we also used an anti-α2
laminin chain affinity purified preparation from human
placenta that contained only laminins-2 and 4. Despite
using distinct laminin preparations, we did not observe
any augmentation of myocyte maturation; the accumula-
tion of desmin and calponin was similar to control cul-
tures. Each laminin preparation induced a web-like HASM
cells pattern, which is characteristic of that induced by
coating with laminin-1 [22,44]. Collectively, although
our studies with competing peptides indicate endogenous
laminin is required for HASM maturation, it appears that
addition of exogenous laminin is not sufficient to pro-
mote this further.
As our studies with competing peptides established a role
for endogenous laminin expression in determining HASM
phenotype maturation, we profiled laminin chain expres-
sion in cultured myocytes. Under serum-fed conditions,
characterised by the presence of HASM cells of the prolif-
erative/synthetic phenotype, the profile of laminin chain
mRNA consisted predominately of equal abundance of
β1, β2 and γ1 laminin chains, whereas α2 and α1 laminin
chains were less abundant. This is not unexpected given
that the β and γ laminin chains are ubiquitously expressed
[69] and α laminin chain expression chiefly contributes to
the heterogeneity seen for tissue-specific and develop-
mental stage-specific expression of the laminin isoforms
[69,76-79].
Our studies revealed that during HASM maturation, there
is a concomitant and significant increase in mRNA and
protein for α2, β1 and γ1 laminin chains. These results
complement our experiments using α and β1 laminin
chain competing peptides that show selective endogenous
laminin expression is a determinant of phenotype matu-
ration. That we observed an increased expression of α2,
β1, and γ1 laminin with phenotype maturation suggests
the involvement of laminin-2 in this process. A number of
studies also show that laminin-1 is prominent in the
developing lung where it determines mesenchymal cell
differentiation, and thereafter laminin-2 accumulates in
the adult lung airways [15-17,80,81]. Moreover, our focus
on laminin chains that comprise laminin-1 and 2 was due
to a lack of available antibodies to perform a comprehen-
sive survey of all α, β and γ laminin chains [69]. Our stud-
ies provide new insight concerning endogenous laminin
expression by adult HASM cells, and how expression of
specific laminin chains, such as α2, β1, and γ1, correlates
with changes in HASM phenotype. Moreover, these data
suggest that the process of HASM cell maturation may be
regulated intrinsically through changes in the synthesis of
specific laminin chains.
A large number of studies show that dynamic changes in
laminin expression is a key factor in normal lung develop-
ment [16,80,81], and also in a number of pathologies,
including asthma [19,68,82]). In atopic asthmatics whose
epithelial integrity is compromised, increased immunore-
activity for γ2 is seen [67]. There are also a number of stud-
ies that describe differences in laminin chain composition
between allergic asthmatics and non-allergic asthmatics,
including evidence for increases in both α2 and β2 lam-
inin chains [19,67,68,83]. Furthermore, Johnson and col-
leagues [20] report that primary cultured HASM cells
exhibit an altered profile of ECM protein expression,
including a decrease in laminin α1 chain, that may act as
an intrinsic mechanism to promote myocyte prolifera-
tion. Similarly, HASM passively sensitized with serum
from atopic asthmatics produce increased amounts of the
γ1 chain of laminin [21]. In our current study we observed
changes in expression of laminin associated with HASM
maturation in non-proliferating myocytes. We have previ-
ously shown that phenotype maturation is associated
with myocyte hypertrophy [84]. Of note, to date there are
limited numbers of studies that directly demonstrate ASM
cells proliferation in situ [85,86], suggesting myocyte
hypertrophy contributes significantly to increased muscle
mass in airway remodelling. In light of our current study,
it is thus tempting to speculate that documented accumu-
lation of ECM around airway smooth muscle [87,88], and
changes in laminin chain expression in the airways of
asthmatics could contribute to HASM hypertrophy associ-
ated with key features of airway remodelling in chronic
asthma.
Conclusion
There are three major new findings from this study: (1)
endogenously expressed laminin is both required and suf-
ficient for the maturation of HASM to a contractile pheno-
type; (2) exogenous laminin (types 1, 2, 3, 4, 6, 8, and 10)
are not sufficient to augment the phenotype maturation
and accumulation of calponin and desmin that occurs
during prolonged serum deprivation of cultured HASM
cells; and, (3) HASM cells in culture express a unique pro-
file of laminin chains, and appear to selectively increase
expression of α2, β1, and γ1 chains, which comprise lam-
inin-2, in conditions that promote maturation to a con-
tractile phenotype. These results provide strong support
for the role of laminin in the maintenance and regulation
of ASM phenotype in the adult lung and thus, may be an
important mechanism regulating the contribution of
myocytes to airways remodelling in disease states such as
asthma.Respiratory Research 2006, 7:117 http://respiratory-research.com/content/7/1/117
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